• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Arylacetamide deacetylase (AADAC)

ACP02152

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP02152 Target NameAADAC
Target SynonymsDACFormLiquid or Lyophilized powder
Expression Systemin vitro E.coli expression systemExpression Range1-399aa
Mol Weight47.2Protein LengthFull length
PurityGreater than 85% as determined by SDS-PAGE.Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDP22760
Background Information
  • Uniprot Id

    P22760

  • Target Species

    Human

  • Target Name

    AADAC

  • Target Full Name

    Arylacetamide deacetylase

  • Target Function

    Displays cellular triglyceride lipase activity in liver, increases the levels of intracellular fatty acids derived from the hydrolysis of newly formed triglyceride stores and plays a role in very low-density lipoprotein assembly. Displays serine esterase activity in liver. Deacetylates a variety of arylacetamide substrates, including xenobiotic compounds and procarcinogens, converting them to the primary arylamide compounds and increasing their toxicity.

  • Target Subcellular Location

    Endoplasmic reticulum membrane; Single-pass type II membrane protein. Microsome membrane; Single-pass type II membrane protein.

  • Target Protein Families

    'GDXG' lipolytic enzyme family

  • Target Tissue Specificity

    Detected in liver (at protein level). Mainly expressed in liver, small intestine, colon, adrenal gland and bladder.

  • Target Research Area

    Signal Transduction

  • Target Synonyms

    AAAD_HUMAN; Aada; Aadac; Arylacetamide deacetylase (esterase); Arylacetamide deacetylase; CES5A1; DAC

  • Target Background

    Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens

Inquire Recombinant Human Arylacetamide deacetylase (AADAC) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification